BioCentury | Apr 8, 2021
Management Tracks

Fineberg to lead SVB Leerink’s structured finance group; plus Gimv, Syncona, Tessera, NKGen and more

...NKMax America Inc., hired Philip Moody as CFO. Moody served as CFO at PaxVax Inc., BTG plc...
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

...with the Sinopharm unit of China National Biotech Group Corp. Soligenix gained from Boston Scientific’s BTG...
BioCentury | Sep 16, 2019
Company News

Management tracks: Gottlieb joins FasterCures’ board; plus Foghorn, Varian

...Facchini as CMO for interventional oncology. Facchini was CMO and head of medical affairs for BTG Plc...
BioCentury | May 20, 2019
Distillery Techniques

RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

...Pfizer Inc. and Astellas Pharma Inc. market the androgen receptor antagonist Xtandi for prostate cancer. BTG plc...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

...months) Company Product Trial Arm ORR rPFS (months) OS (months) Non-metastatic castration-resistant prostate cancer (nmCRPC) BTG plc...
...HR=0.38, p<0.001) NR (HR=0.71, p=0.045) Placebo (n=554) 18.4 14.8 NR Metastatic hormone-sensitive prostate cancer (mHSPC) BTG plc...
BioCentury | Feb 6, 2019
Distillery Therapeutics

Cancer

...Pfizer Inc. and Astellas Pharma Inc. market the androgen receptor antagonist Xtandi for prostate cancer. BTG plc...
BioCentury | Dec 4, 2018
Distillery Therapeutics

Cancer

...Pfizer Inc. and Astellas Pharma Inc. market the androgen receptor antagonist Xtandi for prostate cancer. BTG plc...
BioCentury | Nov 30, 2018
Company News

Boston Scientific to acquire London-based BTG

...cash. BTG shareholders will receive 840p per share. The acquisition is expected to close 1H19. BTG...
...its pharmaceuticals business is focused on antidotes, such as those to counteract snake venom. BTG plc (LSE:BTG...
...LSE:BTG), London, U.K. Boston Scientific Corp. (NYSE:BSX), Marlborough, Mass. Business: Cancer; Hematology Elizabeth S. Eaton Boston Scientific Corp. BTG plc...
BioCentury | Nov 2, 2018
Company News

J&J appeals district court decision invalidating Zytiga patent

...of Cougar Biotechnology Inc., which received rights to the product from BTG plc (LSE:BTG) in 2004. BTG...
BioCentury | May 30, 2018
Distillery Therapeutics

Cancer

...Casodex for prostate cancer. Pfizer Inc. and Astellas Pharma Inc. market Xtandi for prostate cancer. BTG plc...
Items per page:
1 - 10 of 497
BioCentury | Apr 8, 2021
Management Tracks

Fineberg to lead SVB Leerink’s structured finance group; plus Gimv, Syncona, Tessera, NKGen and more

...NKMax America Inc., hired Philip Moody as CFO. Moody served as CFO at PaxVax Inc., BTG plc...
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

...with the Sinopharm unit of China National Biotech Group Corp. Soligenix gained from Boston Scientific’s BTG...
BioCentury | Sep 16, 2019
Company News

Management tracks: Gottlieb joins FasterCures’ board; plus Foghorn, Varian

...Facchini as CMO for interventional oncology. Facchini was CMO and head of medical affairs for BTG Plc...
BioCentury | May 20, 2019
Distillery Techniques

RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

...Pfizer Inc. and Astellas Pharma Inc. market the androgen receptor antagonist Xtandi for prostate cancer. BTG plc...
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

...months) Company Product Trial Arm ORR rPFS (months) OS (months) Non-metastatic castration-resistant prostate cancer (nmCRPC) BTG plc...
...HR=0.38, p<0.001) NR (HR=0.71, p=0.045) Placebo (n=554) 18.4 14.8 NR Metastatic hormone-sensitive prostate cancer (mHSPC) BTG plc...
BioCentury | Feb 6, 2019
Distillery Therapeutics

Cancer

...Pfizer Inc. and Astellas Pharma Inc. market the androgen receptor antagonist Xtandi for prostate cancer. BTG plc...
BioCentury | Dec 4, 2018
Distillery Therapeutics

Cancer

...Pfizer Inc. and Astellas Pharma Inc. market the androgen receptor antagonist Xtandi for prostate cancer. BTG plc...
BioCentury | Nov 30, 2018
Company News

Boston Scientific to acquire London-based BTG

...cash. BTG shareholders will receive 840p per share. The acquisition is expected to close 1H19. BTG...
...its pharmaceuticals business is focused on antidotes, such as those to counteract snake venom. BTG plc (LSE:BTG...
...LSE:BTG), London, U.K. Boston Scientific Corp. (NYSE:BSX), Marlborough, Mass. Business: Cancer; Hematology Elizabeth S. Eaton Boston Scientific Corp. BTG plc...
BioCentury | Nov 2, 2018
Company News

J&J appeals district court decision invalidating Zytiga patent

...of Cougar Biotechnology Inc., which received rights to the product from BTG plc (LSE:BTG) in 2004. BTG...
BioCentury | May 30, 2018
Distillery Therapeutics

Cancer

...Casodex for prostate cancer. Pfizer Inc. and Astellas Pharma Inc. market Xtandi for prostate cancer. BTG plc...
Items per page:
1 - 10 of 497